Livedoid Vasculopathy
Conditions
Interventions
Observation group:None
Sponsors
The First Affiliated Hospital of Air Force Medical University
Eligibility
Sex/Gender
All
Age
14 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Aged 14 to 60 years old (inclusive of 14 and 60 years), no gender restriction; 2. Confirmed diagnosis of livedoid vasculopathy based on clinical manifestations and cutaneous histopathological examination: (1) Clinical manifestations including livedo reticularis purpura, cutaneous ulcer, atrophie blanche, livedo reticularis, etc.; (2) Histopathological findings showing fibrinoid degeneration of dermal vascular walls, intraluminal fibrin deposition or thrombosis, accompanied by varying degrees of lymphocytic infiltration; with patient body weight >= 40 kg; 3. Active stage of disease, presenting with obvious erythema and ulcers, and Numerical Rating Scale (NRS) score >= 4 points; 4. Clinically assessed by physicians to be suitable for combination therapy with tofacitinib and rivaroxaban; 5. Voluntarily sign the informed consent form and agree to cooperate with the implementation of this study.
Exclusion criteria
Exclusion criteria: 1. Patients treated with rivaroxaban alone or tofacitinib alone; 2. Patients unable to cooperate with study follow-up visits and completion of electronic questionnaires; 3. Cases with incomplete clinical data or follow-up data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical Disease Severity Score;Numerical Rating Scale for Pain;Dermatology Quality of Life index(DLQI); | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events, serious adverse events.; | — |
Countries
China
Contacts
Public ContactWang Lei
The First Affiliated Hospital of Air Force Medical University
Outcome results
None listed